Summary of findings 6. Fluoxetine compared to bupropion.
| Fluoxetine compared to bupropion | ||||||
| Patient or population: patients with depression Settings: in‐ and outpatients Intervention: fluoxetine Comparison: bupropion | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Bupropion | Fluoxetine | |||||
|
Failure to respond (reduction ≥ 50% on HDRS) |
493 per 1000 | 447 per 1000 (318 to 582) | OR 0.83 (0.48 to 1.43) | 436 (2 studies) | ⊕⊕⊕⊝ moderate1 | |
|
Endpoint score (HDRS or MADRS) |
The mean endpoint score in the intervention groups was 0 standard deviations higher (0 to 0 higher) | 0 (0) | No data available on this outcome | |||
| Failure to complete ‐ total ‐ | 356 per 1000 | 356 per 1000 (270 to 450) | OR 1.00 (0.67 to 1.48) | 436 (2 studies) | ⊕⊕⊕⊝ moderate1 | |
| Failure to complete ‐ inefficacy ‐ | 23 per 1000 | 0 per 1000 (0 to 87) | OR 1.16 (0.33 to 4.10) | 436 (2 studies) | ⊕⊕⊕⊝ moderate1 | |
| Failure to complete ‐ side effects ‐ | 59 per 1000 | 60 per 1000 (28 to 124) | OR 1.01 (0.45 to 2.25) | 436 (2 studies) | ⊕⊕⊕⊝ moderate1 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; OR: Odds ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.